New hope for tough lung cancers: experimental combo targets resistant tumors
NCT ID NCT06879717
First seen Jan 17, 2026 · Last updated May 09, 2026 · Updated 16 times
Summary
This study tests a new drug combination (roginolisib plus dostarlimab, with or without docetaxel) in 45 adults with advanced non-squamous lung cancer that has worsened after standard treatments. The goal is to see if the combination can shrink tumors or slow disease progression by targeting the immune system. Participants must have good performance status and measurable disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Delta VZW
Roeselare, 8800, Belgium
-
Antwerp University Hospital
Antwerp, 2650, Belgium
-
Hospital Universitari Son Espases
Palma, 07120, Spain
-
Hospital Universitario y Politécnico La Fe
Valencia, 46026, Spain
-
Humanitas University, Department of Medical Oncology
Rozzano, Milan, 20072, Italy
-
Institut Català d'Oncologia Hospitalet
Barcelona, 08908, Spain
-
Istituto Romagnolo per lo studio dei Tumori "Dino Amadori"
Meldola, Forlì-Cesena, 47014, Italy
Conditions
Explore the condition pages connected to this study.